Clinical trials: Follicular Lymphomas
Opioid Use Disorder, Moderate
Study of LYN-014 in Individuals With Opioid Use Disorder Who Are Stable on Methadone Therapy
A Phase 1, Single Dose, Open-label, Safety, Tolerability, and Pharmacokinetic Study of LYN-014 in Individuals with Opioid Use Disorder Who are Stable on Methadone Therapy
- Trial name
- NCT05251376
- Testing
- Levomethadone HCl, Methadone, Morphine Sulfate
- Sponsor
- Lyndra Inc.
Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
This multi-center, open-label, single-arm study will evaluate the pharmacokinetics and safety of obinutuzumab in participants with cluster of differentiation (CD) 20 positive (+) malignant disease.
- Trial name
- NCT01680991
- Testing
- Obinutuzumab
- Where
- 4 sites in China
- Volunteers
- 48 people
- Sponsor
- Hoffmann-La Roche
Lymphoma
A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma
This randomized, open-label study will compare the efficacy and safety of MabThera/Rituxan (rituximab) alone, and in combination with Roferon-A (interferon alfa-2a) in patients with follicular or other CD20+ low-grade lymphoma.
- Trial name
- NCT01609010
- Testing
- rituximab, interferon-a-2a
- Where
- 31 sites in Denmark, Norway and 1 more
- Volunteers
- 313 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
This study will provide continuing availability to tazemetostat for people that have previously completed participation in a tazemetostat study, either with monotherapy (single drug treatment) or combination therapy.
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epithelioid Sarcoma (ES)
- Trial name
- TRuST (NCT02875548)
- Testing
- Tazemetostat
- Where
- 34 sites in United States, Australia and 5 more
- Volunteers
- 58 people
- Sponsor
- Epizyme, Inc.
Follicular Lymphoma
Assessing the Experience of Patients Undergoing Follicular Lymphoma Clinical Research
Historically, participation in medical studies is highly skewed towards particular demographic groups of people. This research will invite several participants to gather a wide range of information on clinical trial experiences…
- Trial name
- NCT06049485
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Chronic Lymphoid Leukemia, Lymphoid Malignancies
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
The Phase 1 portion of the study evaluated the pharmacokinetic profile and safety of ABT-263 with the objective of defining the dose limiting toxicity and maximum tolerated dose in subjects with lymphoid malignancies.
- Conditions
- Chronic Lymphoid Leukemia, Lymphoid Malignancies, Non-Hodgkin's Lymphoma, Follicular Lymphoma
- Trial name
- NCT00406809
- Testing
- ABT-263
- Where
- 12 sites in United States, Canada
- Volunteers
- 81 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Follicular Lymphoma
Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma
This study will assess the safety and efficacy of HCD122 (Lucatumumab) when combined with bendamustine in patients with follicular lymphoma.
- Trial name
- LIFT (NCT01275209)
- Testing
- HCD122
- Where
- 12 sites in United States, Australia and 5 more
- Volunteers
- 1 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Evaluating the Safety and Feasibility of TLD for the Treatment of Severe Asthma
Prospective, multicenter, single-arm (non-randomized) study of Targeted Lung Denervation (TLD) Therapy in subjects with severe asthma.
- Trial name
- RELIEF-1 (NCT02872298)
- Testing
- Targeted Lung Denervation (TLD)
- Where
- 9 sites in France, Germany and 2 more
- Volunteers
- 2 people
- Sponsor
- Nuvaira, Inc.
Severe COVID-19
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
The purpose of this Phase 2 study is to test safety, efficacy, and tolerability of an oral preparation of VB-201 in patients with severe COVID-19
- Trial name
- NCT04733833
- Testing
- VB-201 + Standard of care, Standard of care
- Where
- Israel
- Volunteers
- 5 people
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
Mild and Moderate Hepatic Impairment
Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function
An Open-label, Single-center, Parallel-group Study to Assess Pharmacokinetics, Safety, and Tolerability of a Single Dose of MT-7117 in Subjects with Normal and Impaired Hepatic Function
- Trial name
- NCT04116476
- Testing
- MT-7117
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma America, Inc.
Diffuse Large B-Cell Lymphoma
An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL).
- Trial name
- NCT01340443
- Where
- 24 sites in China
- Volunteers
- 314 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
This is a phase II study evaluating the safety, tolerability and efficacy of BKM120 in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) or follicular lymphoma (FL).
- Trial name
- NCT01693614
- Testing
- Buparlisib
- Where
- 20 sites in United States, Belgium and 6 more
- Volunteers
- 72 people
- Sponsor
- Novartis Pharmaceuticals
Follicular Lymphoma
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study to evaluate the efficacy and safety of ibrutinib in combination with rituximab versus placebo in combination with rituximab in treatment naïve…
- Trial name
- NCT02947347
- Testing
- Ibrutinib Oral Capsule, Rituximab
- Where
- 128 sites in United States, Australia and 17 more
- Volunteers
- 445 people
- Sponsor
- Pharmacyclics LLC.
Follicular Lymphoma, Small Lymphocytic Lymphoma
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
The primary objective of this study is to evaluate the overall response rate (ORR) and complete response (CR) rate to treatment with idelalisib in combination with rituximab in previously untreated adults with follicular lymphoma…
- Trial name
- NCT02258529
- Testing
- Idelalisib, Rituximab
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Gilead Sciences
Lymphoma, Non-Hodgkin
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-cell NHL.
- Trial name
- MAGNIFY (NCT01996865)
- Testing
- Lenalidomide, Rituximab
- Where
- 126 sites in United States, Germany and 1 more
- Volunteers
- 503 people
- Sponsor
- Celgene
Lymphoma, Follicular
A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan
The primary purpose of the study is to investigate the safety of tazemetostat in participants with relapsed or refractory follicular lymphoma with EZH2 gene mutation under daily clinical practice.
- Trial name
- NCT05228158
- Testing
- Tazemetostat
- Where
- 135 sites in Japan
- Volunteers
- 145 people
- Sponsor
- Eisai Co., Ltd.
Follicular Lymphoma
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma
This is a phase 2, single-arm, open label, multicenter study evaluating the efficacy and safety of the combination of VELCADE, bendamustine, and rituximab in subjects with relapsed or refractory follicular lymphoma, who have…
- Trial name
- VERTICAL (NCT00636792)
- Testing
- VELCADE, Bendamustine, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
The objective of study IOA-244-101 is to determine whether IOA-244 is safe and tolerable in cancer patients (Part A). In addition, the study will assess whether IOA-244 can increase the anti-tumour immune response in patients…
- Conditions
- Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC, Myelofibrosis
- Trial name
- NCT04328844
- Testing
- IOA-244, Avelumab Injection, Pemetrexed
- Where
- 3 sites in Italy, United Kingdom
- Volunteers
- 210 people
- Sponsor
- iOnctura
Alzheimer Disease, Early Onset, Alzheimer Disease
Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)
The Etude Study is a multi-center, four-arm prospective dose-adjusting study designed to assess the tolerability, safety and efficacy of non-invasive sensory stimulation for patients with cognitive impairment.
- Conditions
- Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Dementia, Mild Cognitive Impairment
- Trial name
- NCT03661034
- Testing
- GammaSense Stimulation System (non-invasive, non-significant risk)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cognito Therapeutics, Inc.
Lymphoma, Non-Hodgkin
Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma
Comparison of rituximab versus Iodine I 131 Tositumomab Therapeutic Regimen (Tositumomab and Iodine I 131 Tositumomab or the Bexxar Therapeutic Regimen, formerly called Iodine-131 Anti-B1 Antibody) in subjects with follicular non…
- Trial name
- NCT00268983
- Testing
- Tositumomab and Iodine I 131 Tositumomab, Rituximab
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 14 people
- Sponsor
- GlaxoSmithKline